Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Liquid Embolic System market was valued at USD 315.5 million in 2023. The market is projected to grow from USD 342.8 million in 2024 to reach USD 545.9 million by 2031, exhibiting a CAGR of 6.8% during the forecast period. The U.S. market is estimated at USD 125.3 million in 2024, while China is projected to reach USD 85.2 million by 2031, highlighting the significant growth potential in the Asia-Pacific region.
Liquid Embolic Systems are specialized medical devices used in minimally invasive endovascular procedures to block or reduce blood flow in targeted blood vessels. These systems deliver liquid agents, primarily composed of materials like ethylene vinyl alcohol (EVOH) copolymer, which solidify upon contact with blood to form a cast. This embolization process is crucial for treating a range of conditions, with key product segments including formulations with different concentrations such as 6% EVOH and 8% EVOH.
The market is experiencing steady growth, primarily driven by the rising global incidence of neurological disorders like arteriovenous malformations (AVMs) and the growing prevalence of hypervascular tumors, such as those in the liver. Furthermore, technological advancements that improve the safety and efficacy of these systems, including enhanced delivery microcatheters and more predictable precipitating agents, are contributing to market expansion. While the market is growing, it faces challenges such as the high cost of procedures and the need for highly skilled interventional radiologists and neurosurgeons. Key players operating in this consolidated market include Medtronic, Terumo, and MicroVention, which held a significant combined market share of over 65% in 2023.
Rising Prevalence of Neurovascular Diseases
The global increase in the incidence of neurovascular conditions such as arteriovenous malformations (AVMs), cerebral aneurysms, and hypervascular tumors is a primary driver for the liquid embolic system market. An aging population and improved diagnostic capabilities are leading to higher detection rates of these complex conditions. The minimally invasive nature of endovascular embolization procedures, which utilize liquid embolic agents, is increasingly favored over traditional open surgeries. This trend supports sustained market growth.
Technological Advancements in Embolic Agents
Continuous innovation in the formulation and delivery of liquid embolics is significantly propelling the market. The development of advanced non-adhesive agents like precipitating hydrophobic injectable liquid (PHIL) and ethylene vinyl alcohol copolymer (Onyx) has revolutionized treatment. These next-generation agents offer improved control, predictability, and safety profiles during complex embolization procedures. Enhanced imaging compatibility and the development of customizable viscosity options are expanding the clinical applications for these systems.
➤ The global shift towards minimally invasive surgical techniques is a cornerstone of market expansion, with liquid embolization providing significant benefits in patient recovery times and hospital stays.
Furthermore, growing physician training and expertise in interventional neurology and radiology are increasing the adoption rates of these sophisticated systems. The establishment of specialized stroke centers and neurointerventional suites worldwide is creating a robust infrastructure that supports the use of liquid embolic systems, ensuring their integration into standard care pathways.
MARKET CHALLENGES
High Cost of Procedures and Products
The substantial cost associated with liquid embolic systems and the specialized procedures required for their application present a significant challenge. The price of advanced embolic agents and the need for high-resolution imaging equipment like biplane fluoroscopy make these treatments expensive. This can limit adoption in cost-sensitive markets and create reimbursement hurdles with healthcare payers, potentially restricting patient access to these advanced therapies.
Other Challenges
Technical Complexity and Steep Learning Curve
The successful application of liquid embolic systems requires a high degree of technical skill and procedural expertise. Inadequate operator experience can lead to complications such as non-target embolization or incomplete occlusion of the lesion. This steep learning curve necessitates extensive, costly training programs, which can be a barrier to widespread adoption, particularly in regions with limited access to specialized medical training.
Risk of Complications
Despite technological advancements, risks such as glue catheter entrapment, inflammation reactions, and recanalization of the embolized vessel remain concerns. Managing these potential adverse events requires careful patient selection and meticulous technique, which can deter some clinicians from utilizing these systems for complex cases.
Stringent Regulatory Approvals
The liquid embolic system market is subject to rigorous regulatory scrutiny from bodies like the U.S. FDA and the European Medicines Agency. The lengthy and costly process of obtaining approvals for new devices or indications can delay market entry for innovative products. This regulatory burden can slow down the pace of innovation and limit the availability of new treatment options for patients.
Limited Reimbursement Policies
Inconsistent and limited reimbursement coverage for neurovascular embolization procedures using liquid agents acts as a major market restraint. Healthcare systems in many countries have complex reimbursement pathways that may not fully cover the cost of these advanced devices and procedures. This financial disincentive can hinder hospital adoption and physician utilization, particularly in public healthcare systems with constrained budgets.
Expansion into Emerging Economies
There is significant untapped potential in emerging markets across Asia-Pacific, Latin America, and the Middle East. Rising healthcare expenditure, improving medical infrastructure, and growing awareness of minimally invasive treatment options are creating fertile ground for market expansion. Companies that develop cost-effective solutions and establish strong local partnerships are well-positioned to capitalize on this growth.
Development of Novel Applications
Opportunities abound in expanding the clinical applications of liquid embolic systems beyond traditional neurovascular uses. Research is exploring their efficacy in embolizing visceral aneurysms, treating varicoceles, and managing traumatic hemorrhage. Successful expansion into these new therapeutic areas could substantially broaden the patient population and drive significant market growth.
Product Innovation and Portfolio Diversification
Continuous investment in R&D to create next-generation embolic agents with improved properties such as higher radiopacity, biodegradability, and controlled polymerization times represents a key opportunity. Developing systems tailored for specific anatomical challenges or patient populations can help companies differentiate their products and capture niche market segments, fostering long-term growth.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
6% EVOH is the leading segment, favored for its optimal balance between cohesive properties and controlled precipitation, which provides enhanced precision and safety during delicate neurovascular embolization procedures. This formulation offers predictable vessel penetration and solidification, making it the preferred choice for complex interventions. The 8% EVOH formulation delivers a more viscous solution, suited for procedures requiring rapid occlusion of high-flow lesions, though its adoption is tempered by the need for greater operator expertise to manage its faster polymerization rates. |
| By Application |
|
Arteriovenous Malformations (AVMs) constitute the leading application segment, driven by the critical need for precise, non-invasive treatment options for these complex vascular anomalies. Liquid embolic systems offer superior capabilities in navigating tortuous vasculature to occlude feeder vessels effectively, reducing the risk of rupture and associated neurological sequelae. The application for treating hypervascular tumors is also significant, particularly for preoperative embolization to minimize surgical blood loss, while other applications encompass a range of hemorrhagic conditions and vascular pathologies. |
| By End User |
|
Hospitals represent the dominant end-user segment due to their comprehensive infrastructure, availability of advanced imaging technologies like biplane angiography systems, and the presence of multidisciplinary teams including neurointerventional radiologists and neurologists required for complex embolization procedures. The high procedural volume and ability to manage post-operative care solidify their leadership. Specialty clinics are gaining traction for focused neurovascular care, while ambulatory surgical centers are increasingly adopted for select, less complex outpatient embolization procedures, driven by cost-effectiveness and patient convenience. |
| By Technology |
|
Precipitating Liquid Embolic technology, exemplified by ethylene vinyl alcohol copolymer solutions, is the leading segment owing to its unique in-situ precipitation mechanism upon contact with blood ions. This provides unparalleled control for filling complex vascular networks with a cast-like solid, ensuring durable occlusion. Non-precipitating agents like cyanoacrylates offer rapid adhesion but present handling challenges. Coil-assisted embolization is an emerging hybrid technique that combines the penetration of liquids with the structural support of coils, particularly beneficial for wide-necked aneurysms, enhancing procedural efficacy and safety. |
| By Vessel Size |
|
Small-to-Medium Vessels represent the leading segment for liquid embolic system application, as this range includes the critical feeder vessels associated with AVMs and tumors where precise, deep penetration is paramount. The flow-directed properties of liquid embolics are ideally suited for navigating these complex, often tortuous pathways. Embolization of micro-vessels is highly challenging and requires agents with extremely low viscosity, while large vessel occlusion is often better addressed with alternative modalities like vascular plugs or coils, though liquid embolics can be used adjunctively to ensure complete closure. |
A Market Dominated by Established MedTech Giants with Emerging Niche Players
The global Liquid Embolic System market is characterized by a consolidated competitive structure where a few major multinational medical device corporations hold a significant share of the market. In 2024, the top five players collectively accounted for a substantial percentage of the global revenue. The clear leader is Medtronic, whose Onyx liquid embolic system remains a gold standard for the treatment of arteriovenous malformations (AVMs). Following closely are other industry titans like Terumo and CERENOVUS (a Johnson & Johnson company), which have strong portfolios and extensive global distribution networks that solidify their market positions. These leading companies compete on the basis of technological innovation, product efficacy, clinical data support, and robust physician training programs, creating a high barrier to entry for new participants.
Beyond the dominant players, the market includes several significant manufacturers that cater to niche segments and specific geographical regions. Companies such as Balt Extrusion, with its proprietary polymers, and MicroVention (a part of Terumo), are key innovators in the space. The market also features growing contributions from emerging manufacturers, particularly in the Asia-Pacific region, such as Meril Life Sciences from India and Saikesaisi Holding. These companies often compete by offering cost-effective alternatives and focusing on expanding access to embolization procedures in developing markets, thereby contributing to the overall growth and diversification of the Liquid Embolic System landscape.
List of Key Liquid Embolic System Companies ProfiledMedtronic plc
CERENOVUS (Johnson & Johnson)
Meril Life Sciences Pvt. Ltd.
Saikesaisi Holdings Group Co., Ltd.
Stryker Corporation
Kaneka Medix Corporation
Cook Medical
Shape Memory Medical, Inc.
Phenox GmbH
Acandis GmbH
Rapid Medical
The global Liquid Embolic System market is on a strong upward trajectory, reflecting its critical role in interventional neurology and radiology. Valued at an estimated million in 2024, the market is projected to reach US$ million by 2032, growing at a steady compound annual growth rate. This expansion is driven by the increasing global incidence of neurovascular conditions such as arteriovenous malformations (AVMs) and hypervascular tumors, for which liquid embolic agents are a primary treatment modality. The demand is further amplified by technological advancements in delivery systems and a growing preference for minimally invasive surgical procedures over traditional open surgeries, leading to shorter hospital stays and improved patient recovery times.
Other TrendsDominance of the 6% EVOH Segment
The 6% EVOH (Ethylene Vinyl Alcohol Copolymer) segment is a significant driver within the market, projected to reach $ million by 2032 with a robust CAGR over the next six years. This specific concentration offers an optimal balance between viscosity and controllability for physicians, making it a preferred choice for precise embolization procedures. Its dominance is expected to continue as it remains the gold standard for treating complex neurovascular pathologies, supported by extensive clinical evidence and surgeon familiarity.
Consolidated Market Landscape with Key PlayersThe competitive landscape of the Liquid Embolic System market is characterized by the presence of established global medical technology companies. In 2024, the top five players, including Medtronic, Terumo, and Balt, collectively held a significant share of the global revenue, approximately percent. This concentration indicates a high barrier to entry due to stringent regulatory requirements and the need for substantial R&D investment. These leading companies are focused on strategic initiatives such as product innovation, mergers, and acquisitions to strengthen their market positions and expand their geographic footprint, particularly in high-growth regions like Asia. The North American market, with the U.S. estimated at $ million in 2024, remains a major revenue generator, while China is poised for substantial growth, expected to reach $ million, highlighting the shifting dynamics of global demand.
Regional Analysis: Liquid Embolic System MarketEurope
Europe represents a mature and significant market for liquid embolic systems, characterized by robust public healthcare systems and strong clinical guidelines. Countries like Germany, France, and the United Kingdom are at the forefront, with high procedural volumes for treating cerebral AVMs and hypervascular tumors. The region benefits from collaborative research networks and a harmonized regulatory approach through the MDR, which ensures high safety standards. While reimbursement policies can vary between national health services, there is generally strong support for evidence-based interventions. The presence of leading academic institutions contributes to a steady advancement in embolization techniques and materials, although adoption of the very latest technologies can sometimes be slower than in North America due to more conservative budgeting and procurement processes within public health systems.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for liquid embolic systems, driven by improving healthcare infrastructure, rising healthcare expenditures, and a growing awareness of minimally invasive treatment options. Japan and Australia are well-established markets with advanced medical capabilities, while China and India are experiencing explosive growth due to their vast patient populations and increasing investment in specialized neurosurgery and interventional radiology departments. The market growth is supported by local manufacturing initiatives and the entrance of regional players, which helps make these technologies more accessible. However, challenges remain, including varying levels of reimbursement coverage and a need for more specialized physician training in some emerging economies, which currently moderates the pace of adoption compared to Western markets.
South America
The liquid embolic system market in South America is emerging, with growth potential tied to economic development and healthcare modernization. Brazil is the largest market in the region, supported by a sizable patient population and an increasing number of trained interventional radiologists. Market expansion is primarily driven by the rising incidence of neurovascular diseases and gradual improvements in hospital capabilities in major urban centers. However, market growth is constrained by economic volatility in some countries, which impacts healthcare budgeting and limits access to expensive medical technologies. Regulatory processes and reimbursement frameworks are also less established compared to North America or Europe, presenting both a challenge and an opportunity for market players willing to navigate these dynamics.
Middle East & Africa
The Middle East & Africa region presents a highly diverse market landscape. Wealthier Gulf Cooperation Council (GCC) countries, such as Saudi Arabia and the UAE, have modern healthcare systems with high adoption rates of advanced medical technologies, including liquid embolic systems, driven by government investment and medical tourism. In contrast, the broader African market remains largely underpenetrated due to significant infrastructural challenges, limited access to specialized care, and budget constraints. The overall market growth is nascent but promising, fueled by increasing healthcare investments in key Middle Eastern economies and humanitarian efforts to build neurointerventional capacity in certain African nations, though it remains the smallest regional market globally.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
极By end-user industry
极 By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape极
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Liquid Embolic System market was valued at USD 315.5 million in 2023 and is projected to reach USD 545.9 million by 2031, growing at a CAGR of 6.8% during the forecast period.
-> Key players include Medtronic, Terumo, Balt, MicroVention, CERENOVUS, Meril Life, and Saikesaisi Holding, among others.
-> Key growth drivers include rising incidence of neurological disorders, growing prevalence of hypervascular tumors, and technological advancements.
-> Asia-Pacific shows significant growth potential, with China projected to reach USD 85.2 million by 2031.
-> Emerging trends include enhanced delivery microcatheters, more predictable precipitating agents, and innovations in embolic materials.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates